Navigation Links
HIV pays a price for invisibility
Date:4/12/2009

Mutations that help HIV hide from the immune system undermine the virus's ability to replicate, show an international team of researchers in the April 13 issue of the Journal of Experimental Medicine. The study was published online on March 23.

When HIV infects a cell, a complex of human immune proteins called HLA (short for human leukocyte antigen) alert killer T cells by displaying bits of the virus on the surface of the cell. The T cells recognize these HIV fragments and mobilize an attack.

Individuals who have certain types of HLA proteins control infection better than others. In people with HLA-B*5703, for example, the virus multiplies less than in people with some other HLA variantslikely because killer T cells in these individuals are quick to attack infected cells. But HIV is tricky. To get around HLA-B*5703, the virus mutates three amino acids that T cells need to recognize the infected cells, causing the killers to pass by the infected cell unnoticed. Thus by mutating, the virus becomes invisible to the immune system.

In the new report, Hayley Crawford at the University of Oxford and colleagues show that the virus pays a price for its invisibility. The triple mutant replicated 20 times slower than normal in cell culture.

The researchers went on to study Zambian couples in which one HLA-B*5703-expressing person infected with triple-mutant virus passed the infection to a partner who either did or didn't have the same HLA variant. When transmitted to a person without HLAB*5703, the virus changed its mutated amino acids back to their original sequence, most likely because the benefit of avoiding killer T cells no longer outweighed the cost of reduced replication. However, when transmitted to another HLA-B*5703-expressing person, the triple-mutated virus came out on top despite its reduced replication. In these individuals, the avoidance of killer T cells allowed the infection to rapidly proceed to clinical illness. This study suggests that vaccines should be designed to produce a T cell response against a number of different viral peptides something that experimental human vaccines so far have yet to achieve.


'/>"/>

Contact: Amy Maxmen
amaxmen@rockefeller.edu
Rockefeller University Press
Source:Eurekalert

Related biology news :

1. Tom Cruise smile comes with a sunburn price
2. World fertilizer prices drop dramatically after soaring to all-time highs
3. Rising energy, food prices major threats to wetlands as farmers eye new areas for crops
4. Research yields pricey chemicals from biodiesel waste
5. Baker Institute study finds continuing upward pressure on retail gasoline prices
6. Price of lower-calorie foods rising drastically, researchers find
7. Rising food prices threaten worlds poor people
8. Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... Mass. (PRWEB) , ... March 22, 2017 , ... ... scale up human tissue regeneration from small lab samples to full-size tissues, bones, ... how to establish a vascular system that delivers blood deep into the developing ...
Breaking Biology Technology: